IONQ IonQ, Inc. Insider Trading

Director William Teuber buys 3,000 IONQ shares at $38.38 as stock down 53.3% from 52-week high; stock now at $38.37.

Director William Teuber purchased 3,000 shares of IonQ at $38.38 on 2026-02-27, increasing his holdings by 46.8% to 9,413 shares total. The purchase occurred while the stock trades at $38.37, down 53.3% from its 52-week high of $82.09 and down 16.2% over the past 30 days. However, Teuber's prior open-market buy at this ticker on 2025-11-11 showed poor timing, declining 35.3% over the subsequent 90-day period, and his cross-ticker track record reflects an 0% win rate across 1 prior buy with an average 90-day return of -35.3%. IonQ remains unprofitable (net income $-1.1B in the latest full fiscal year), though it reported 201.8% annual revenue growth and quarterly revenue of $39.9M. The transaction's significance is modest given the director's historically unsuccessful market timing, the company's loss-making status, and the stock's ongoing price weakness despite the purchase.

Director Kathryn K. Chou sold 20,000 IONQ shares at $51.40; stock now $50.35, down -38.7% from 52-week high.

Director Kathryn K. Chou sold 20,000 shares on 2025-12-11 at $51.40, reducing her holdings by 24.7% from 80,839 to 60,839 shares. The transaction occurred while IONQ trades 38.7% below its 52-week high of $82.09, near the lower end of its 52-week range. Her prior IONQ sale on 2025-06-11 was followed by a 90-day return of +8.7%, indicating the stock rose substantially after that earlier insider sale—a poorly-timed outcome from an insider perspective. The company remains unprofitable with a negative annual net income of $-1.1B despite strong revenue growth of 95.4% year-over-year, presenting a contrasting fundamental picture between growth trajectory and profitability headwinds.

CRO Alameddine Rima sold 100,000 shares of IONQ at $46.89; stock now $41.71, down 49.2% from 52-week high.

Rima sold 100,000 shares (18.8% of her pre-transaction holdings) at $46.89 on 2025-11-20, retaining 432,616 shares post-sale. The sale occurred near the middle of IONQ's 52-week range and well before the current price of $41.71, which is 49.2% below the 52-week high of $82.09. Examining timing context: across her cross-ticker track record, Rima's 6 prior sells have averaged +9.6% 30-day return and +6.2% 90-day return, with a well-timed rate of 40.00%, suggesting modest success predicting downturns. At IONQ specifically, her prior 5 trades show mixed timing—only 1 of 4 measurable 90-day outcomes was well-timed (negative return), with her most recent IONQ sale on 2025-09-11 posting +59.1% 30-day return (poorly timed). The company remains unprofitable with $-1.1B net income over its latest full fiscal year, though annual revenue growth is strong at 95.4%, creating a disconnect between near-term fundamentals and valuation. The 30-day decline of 24.8% post-transaction and the stock's recent weakness merit observation against her historical track record at this ticker.

IONQ director Teuber buys 2,000 shares at $54.82; stock now $45.40, down 41.5% in 30 days.

Director William J Teuber Jr purchased 2,000 shares at $54.82 on 2025-11-11, increasing his holdings from 4,413 to 6,413 shares—a 45.3% increase in his position. The purchase price sits well above the current market price of $45.40, and the stock has declined 41.5% over the preceding 30 days and is trading 44.7% below its 52-week high of $82.09. IONQ reported $39.9M in quarterly revenue with 95.4% annual revenue growth, but the company posted a net loss of $-1.1B in its most recent fiscal year and remains unprofitable. The insider's acquisition at a substantially higher price point than today's market, combined with the company's ongoing unprofitability despite strong revenue growth and recent sharp stock deterioration, creates a complex signal that merits scrutiny of both the transaction timing and the company's path to profitability.

IonQ CEO de Masi sold 16,120 shares at $44.40 on 2025-09-11; stock now $55.61 (+34.9% in 30d).

de Masi Niccolo, President and CEO, sold 16,120 shares (1.3% of pre-transaction holdings) at $44.40, reducing his stake from 1,197,306 to 1,181,186 shares. The stock has since appreciated to $55.61, representing a 30-day gain of +34.9% from the sale date. Across his cross-ticker track record, the insider's 10 prior sells averaged +13.9% returns over 30 days and +32.7% over 90 days, with a 0.00% well-timed rate at the 90-day mark, meaning those sales preceded gains rather than declines. At IONQ specifically, his single prior sale on 2025-06-11 saw the stock rise +3.6% in 30 days and +9.1% in 90 days, also not well-timed. The company is unprofitable (annual net income: $-176.8M) despite strong revenue growth of +95.4% year-over-year and a $16.5B market capitalization.

CRO Rima sells 19,976 shares at $44.40 on IONQ; stock now at 52-week high $55.61

Alameddine Rima, Chief Revenue Officer, sold 19,976 shares at $44.40 on 2025-09-11, reducing holdings from 552,592 to 532,616 shares—a -3.6% reduction. The sale occurred at a price 20% below the current market level of $55.61, which is at the 52-week high. IonQ is unprofitable with net income of $-176,838,000.00 on quarterly revenue of $20,694,000.00, though the company exhibits strong growth with +95.4% annual revenue expansion. Across his prior four measurable trades at IONQ, Rima was well-timed 50% of the time at the 90-day mark—neither a strong nor weak pattern. His cross-ticker track record shows a 50.00% well-timed rate with an average 90-day return of -6.9% after sells, indicating near-neutral historical timing acumen. With the stock recently up 34.9% over 30 days and 47.0% over 90 days, this sale occurred well into a sustained rally; whether the transaction reflects portfolio rebalancing or conviction about near-term price weakness cannot be determined from the filing alone.

CFO Kramer sells 64,578 shares of IONQ at $41.82 for $2.7M, reducing holdings by 12.0%

CFO Thomas G. Kramer sold 64,578 shares (64.6K shares) at $41.82 on 2025-09-03, bringing his holdings from 537,880 to 473,302 shares (a 12.0% reduction). The sale price stands 18.2% below the 52-week high of $51.07, while the stock has gained 1.4% over the past 30 days and 7.1% over 90 days. Kramer has executed five consecutive sales at IONQ since mid-June, with mixed recent pricing signals: his most recent prior sale on 2025-08-06 showed a 1.3% 30-day gain, while his July 21 and July 8 sales faced subsequent declines of 22.9% and 15.2% respectively. Against this backdrop of repeated selling, the company remains unprofitable with a full-year net loss of $-176,838,000.00 despite strong revenue growth of 95.4% year-over-year, adding context to the consistent liquidation pattern.

Director Singh sells 50,480 shares (-90.2% of holdings) for $2.2M at $43.02, retaining 5.5K; IONQ stock down -21.2% from 52-week high, losses widening.

Singh Inder M, a Director, executed a substantial reduction of his IONQ position, selling 50,480 shares (50.5K shares) for $2,171,801.04 ($2.2M) at $43.02 on 2025-08-13, leaving 5,513 shares (5.5K shares) post-transaction—a -90.2% reduction in his prior holdings of 55,993 shares (56.0K shares). This follows another sell at IONQ just 12 days earlier (2025-08-01), signaling sequential reduction of stake rather than isolated disposition. IONQ is unprofitable with net income of $-176,838,000.00 ($-176.8M) over its most recent full fiscal year, and the stock currently trades at $40.23—down -21.2% from its 52-week high of $51.07 and down -7.6% over the past 30 days. His cross-ticker track record shows 2 prior sells with an average 30-day return of +6.7%, but at IONQ specifically, his June 2025 sell has posted a +6.7% 30-day return; the measurable timing pattern at this ticker provides limited basis for extrapolation given limited prior outcomes.

CFO Thomas Kramer sells 17,776 shares of IONQ at $41.28; 5th consecutive sale in 16 days amid -18.0% decline from 52-week high

Thomas Kramer, Chief Financial Officer of IonQ, sold 17,776 shares at $41.28 on 2025-08-06, reducing his holdings from 555,656 to 537,880 shares. This sale is the fifth consecutive open-market sell transaction at IONQ within 16 days (sales on 2025-07-21, 2025-07-08, 2025-07-02, 2025-06-16, and today), a concentration of liquidation activity that warrants investor attention. The stock is trading -18.0% from its 52-week high of $51.07 and has declined 8.1% over the past 30 days, even as the company reports annual revenue growth of +95.4%. The company remains unprofitable (net income of $-176.8M in the latest full fiscal year), and Kramer's insider sales at IONQ have underperformed: his three most recent trades with measurable outcomes posted 30-day returns of -15.2%, -9.8%, and +14.2%, while his one completed 90-day outcome at this ticker (2024-09-12 sale) was well-timed with a subsequent 308.2% gain. The repeated sell pattern over a compressed timeframe, combined with current technical weakness, suggests the insider is reducing exposure during a vulnerable period in the stock's performance.

Director Singh sold 37,090 shares (87.1% of holdings) at $38.28, reducing stake to 5.5K shares as IONQ stock is -5.3% in 30 days

Singh Inder M, a director at IonQ, executed a substantial reduction of his equity position, selling 37,090 shares (37.1K shares) at $38.28 on 2025-08-01 for $1.4M, which represents an 87.1% reduction in his pre-transaction holdings of 42,603 shares (42.6K shares), leaving him with 5.5K shares post-transaction. The sale price of $38.28 was above the current market price of $42.02, and occurred at $42.02 compared to the 52-week high of $51.07—indicating a -17.7% discount from recent peaks. In his prior transaction at IONQ on 2025-06-12, Singh sold shares that showed a 30-day return of +6.7%, though a 90-day outcome is not yet measurable for that earlier trade. The company remains unprofitable with quarterly revenue of $7.6M and net income of -$32.3M despite strong annual revenue growth of +95.4%, a context where a near-total director position liquidation may signal rebalancing of concentrated equity exposure rather than confidence in near-term stock performance.